Clinical trial · Observational
Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
Prospective Analysis of Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
NCT03680677CI-TRIAL-00121745recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia, Acute | Acute Leukemia | ONTOLOGY_EXACT | 0.90 |
| MDS | Myelodysplastic Syndrome | CURATED_BROADER | 0.80 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bone Marrow or Peripheral Blood Graft (BMT) | Procedure | — | UNRESOLVED |
| Cancer-directed Therapy or Best Supportive Care | Other | — | UNRESOLVED |
| Frailty Assessment | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Cancer Directed Therapy or Best Supportive Care
- description
- Cancer-directed therapy with intensive regimens, clinical trial, hypomethylating agent, hypomethylating agent combinations, targeted agents alone, or best supportive care
- interventionNames
- Other: Cancer-directed Therapy or Best Supportive Care
- Diagnostic Test: Frailty Assessment
- label
- Transplant
- description
- Bone marrow or peripheral blood graft (BMT) or CAR T-cell therapy
- interventionNames
- Procedure: Bone Marrow or Peripheral Blood Graft (BMT)
- Diagnostic Test: Frailty Assessment
Primary outcomes (1)
- measure
- Non-Relapse Mortality (NRM) in Frail, Pre-Frail, and Non-Frail patients
- timeFrame
- 1-month
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 60 Years
Show eligibility criteria text
Eligibility Criteria Arm A: * Age 60 years or older. * New diagnosis of Acute Leukemia or MDS, or suspected diagnosis. * Able to consent to the study. Eligibility Criteria Arm B: * Age 60 years or older with a hematologic malignancy. * Plan to undergo an allogeneic blood or marrow transplantation or CAR T-cell therapy. * Able to consent to the study.
References
Publications (0)
Data not yet available
No reference posted for this study.